Project Details
Description
A randomization, multicenter, open-label trial comparing chemotherapy plus trastumab plus pertuzumab versus chemotherapy plus trastuzumab emtasine plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer
| Status | Finished |
|---|---|
| Effective start/end date | 7/1/14 → 11/30/18 |
Funding
- HOFFMANN-LA ROCHE PHARMACEUTICALS
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.